Akums Drugs and Pharmaceuticals Ltd (AKUMS) Q1FY27 Management Mirror - Jun-2026 Qtr
FY27 Corporate EBITDA Margin Guided Toward Upper Bracket of 14-15% Range Following 15.0% Print in Jun'26 Qtr
In the Jun'26 Qtr concall, management reaffirmed its long-term corporate EBITDA margin guidance of 14% to 15%. Given the performance in the quarter, management expects full-year margins to incline toward the upper bracket of this range. Volume growth is expected to remain in the double digits for the remainder of the year. According to the Jun'26 Qtr Quarterly Financial Results, the reported actual consolidated EBITDA margin was 15.0%.
4 more themes on the ELITE plan.